MX2009000400A - Sales monovalentes y divalentes del acido n-(5-hidroxinicotinoil)- l-glutámico que presentan acción psicotrópica (antidepresiva y ansiolítica), neuroprotectora, geroprotectora y cerebroprotectora. - Google Patents

Sales monovalentes y divalentes del acido n-(5-hidroxinicotinoil)- l-glutámico que presentan acción psicotrópica (antidepresiva y ansiolítica), neuroprotectora, geroprotectora y cerebroprotectora.

Info

Publication number
MX2009000400A
MX2009000400A MX2009000400A MX2009000400A MX2009000400A MX 2009000400 A MX2009000400 A MX 2009000400A MX 2009000400 A MX2009000400 A MX 2009000400A MX 2009000400 A MX2009000400 A MX 2009000400A MX 2009000400 A MX2009000400 A MX 2009000400A
Authority
MX
Mexico
Prior art keywords
hydroxynicotinoil
heroprotective
anxyolytic
neuroprotective
antidepressant
Prior art date
Application number
MX2009000400A
Other languages
English (en)
Inventor
Pavel Vasilyevich Yakimuk
Sergey Vitalyevich Stovbun
Alexandr Anatolyevich Litvin
Original Assignee
Obshchestvo S Ogranichennoi Ot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39020154&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009000400(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Obshchestvo S Ogranichennoi Ot filed Critical Obshchestvo S Ogranichennoi Ot
Publication of MX2009000400A publication Critical patent/MX2009000400A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La invención se refiere a medicinas, en particular a sales mono- y divalentes del ácido N-(5-hidroxinicotinoil)-L-glutamínico, que presentan acción psicotrópica antidepresiva, ansiolítica, heroprotectora, neuroprotectora, cerebroprotectora antihipóxica y nootrópica. Los nuevos compuestos difieren de las preparaciones conocidas, incluso de la técnica anterior más parecida en la forma de una base del ácido N-(5-hidroxinicotinoil)-L-glutamínico (nooglucotilo), en que producen efectos psicotrópicos, específicamente acciones antidepresivas, ansiolíticas, neuroprotectoras y heroprotectoras, de tal manera que se reducen los puntos de lesión provocados por ataques de apoplejía y se mejoran las deficiencias neurológicas específicas de la edad y las capacidades de trabajo intelectuales y físicas.
MX2009000400A 2006-07-31 2007-06-06 Sales monovalentes y divalentes del acido n-(5-hidroxinicotinoil)- l-glutámico que presentan acción psicotrópica (antidepresiva y ansiolítica), neuroprotectora, geroprotectora y cerebroprotectora. MX2009000400A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2006127564/04A RU2314293C1 (ru) 2006-07-31 2006-07-31 Одно- и двухвалентные соли n-(5-гидроксиникотиноил)-l-глутаминовой кислоты, обладающие психотропным (антидепрессивным и анксиолитическим), нейропротекторным, геропротекторным и противоинсультным действием
PCT/RU2007/000304 WO2008018815A1 (fr) 2006-07-31 2007-06-06 Sels monovalents ou divalents d'acide n-(5-hydroxynicotinoyl)-l-glutaminique présentant un effet psychotrope (antidépresseur et anxiolytique), neuroprotecteur, géroprotecteur et cérébroprotecteur

Publications (1)

Publication Number Publication Date
MX2009000400A true MX2009000400A (es) 2009-03-02

Family

ID=39020154

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009000400A MX2009000400A (es) 2006-07-31 2007-06-06 Sales monovalentes y divalentes del acido n-(5-hidroxinicotinoil)- l-glutámico que presentan acción psicotrópica (antidepresiva y ansiolítica), neuroprotectora, geroprotectora y cerebroprotectora.

Country Status (14)

Country Link
US (1) US8030493B2 (es)
EP (1) EP2050737A4 (es)
JP (1) JP2009545589A (es)
KR (1) KR101439561B1 (es)
CN (1) CN101500998B (es)
AU (1) AU2007282178A1 (es)
BR (1) BRPI0713814A8 (es)
CA (1) CA2658589A1 (es)
EA (1) EA014855B1 (es)
MX (1) MX2009000400A (es)
NZ (1) NZ574637A (es)
RU (1) RU2314293C1 (es)
UA (1) UA93269C2 (es)
WO (1) WO2008018815A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1368314A1 (ru) * 1984-02-22 1988-01-23 Научно-исследовательский институт фармакологии АМН СССР @ -Никотиноиламинокислоты, обладающие противогипоксической и антиамнестической активностью
RU94038232A (ru) * 1994-10-10 1996-08-27 Научно-исследовательский институт фармакологии Томского научного центра РАМН Средство, улучшающее мозговое кровообращение

Also Published As

Publication number Publication date
KR20090037996A (ko) 2009-04-17
EA014855B1 (ru) 2011-02-28
US8030493B2 (en) 2011-10-04
EA200900274A1 (ru) 2009-06-30
RU2314293C1 (ru) 2008-01-10
BRPI0713814A8 (pt) 2018-01-09
CN101500998A (zh) 2009-08-05
KR101439561B1 (ko) 2014-09-11
EP2050737A4 (en) 2011-05-04
BRPI0713814A2 (pt) 2013-09-17
EP2050737A1 (en) 2009-04-22
CA2658589A1 (en) 2008-02-14
JP2009545589A (ja) 2009-12-24
WO2008018815A1 (fr) 2008-02-14
AU2007282178A1 (en) 2008-02-14
UA93269C2 (en) 2011-01-25
US20090240059A1 (en) 2009-09-24
CN101500998B (zh) 2011-06-01
NZ574637A (en) 2010-10-29

Similar Documents

Publication Publication Date Title
GEP201706776B (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof
MX2010006489A (es) Formas cristalinas de n-(terc-butoxicarbonil)-3-metil-l-valil-(4r) -4-((7-cloro-4-metoxi-1-isoquinolinil)oxi)-n-((1r,2s)-1-((ciclopr opilsulfonil)carbamoil)-2-vinilciclopropil)-l-prolinamida.
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
MY148096A (en) 4,5-diphenyl-pyrimidinyl-amino substituted carboxylic acids, method for the production and use thereof as medicaments
EA201001585A1 (ru) Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк)
MX2009004467A (es) Compuestos benzoilo amino heterociclilo como activadores de la glucoquinasa (glk).
UY30888A1 (es) Procedimiento
MY148483A (en) 4,5-diphenyl-pyrimidinyl-oxy or-mercapto substituted carboxylic acids, method for the production and use thereof as medicaments
MY151986A (en) Adamantyl diamide derivatives and uses of same
TW200718424A (en) Novel compounds of amino sulfonyl derivatives
MX2012013465A (es) Lactamas sustituidas con piperidinilo como moduladores de gpr119.
WO2011054436A8 (de) Halogenalkyl-substituierte amide als insektizide und akarizide
EA200802214A1 (ru) 2,4-диаминопиримидины в качестве ингибиторов киназ, участвующих в регуляции клеточного цикла
MX338551B (es) Nuevos compuestos de piridina fusionada como inhibidores de caseina quinasa.
MX2009010083A (es) Compuestos biarilo y biheteroarilo de utilidad en el tratamiento de trastornos de hierro.
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
MX2011011764A (es) Compuestos de carboxamida y su uso como inhibidores de calpaina.
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
EP2257161A4 (en) AHCY HYDROLASE INHIBITORS FOR THE TREATMENT OF HYPER-HOMOCYSEINEMIA
UA94080C2 (ru) Ациклически-замещенные производные фуропиримидина и их применение для лечения сердечно-сосудистых заболеваний
MX2015003732A (es) Tratamiento de enfermedad de alzheimer leve y moderada.
MX2009002906A (es) Derivados de piridina para el tratamiento de trastornos metabolicos relacionados con la resistencia a insulina o hiperglicemia.
MX2009000767A (es) Sintesis de (2s,5r)-5-etinil-1-{n-(4-metil-1-(4-carboxi-piridin-2- il)piperidin-4-il)glicil}pirrolidina-2-carbonitrilo.
TW200800993A (en) Organic compounds
TW200510372A (en) Novel amides useful for treating pain

Legal Events

Date Code Title Description
FG Grant or registration